Caspase 3 has previously been shown to be synergistically increased when apigenin is used in combination with: (1) TRAIL at 24 h for acute lymphoblastic leukaemia cells (Jurkat) via upregulation of DR5 expression70, (2) Abivertinib at 24 h for diffuse large B-cell lymphoma cells (U2932 and OCI-LY1) via downregulation of PI3K/mTOR expression62; (3) 5-Fluorouracil at 72 h for breast cancer cells (MDA-MB-453) via down regulation of Akt expression57; and (4) Cisplatin for lung cancer cells (A549)61. Here, CASP3 is linked to breast cancer.